Literature DB >> 34421212

Finerenone.

Lauren A Marcath1.   

Abstract

Entities:  

Year:  2021        PMID： 34421212      PMCID： PMC8329022          DOI： 10.2337/cd21-0050

Source DB:  PubMed          Journal:  Clin Diabetes        ISSN： 0891-8929


× No keyword cloud information.
  8 in total

1.  Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy: A Randomized Clinical Trial.

Authors:  George L Bakris; Rajiv Agarwal; Juliana C Chan; Mark E Cooper; Ron T Gansevoort; Hermann Haller; Giuseppe Remuzzi; Peter Rossing; Roland E Schmieder; Christina Nowack; Peter Kolkhof; Amer Joseph; Alexander Pieper; Nina Kimmeskamp-Kirschbaum; Luis M Ruilope
Journal:  JAMA       Date:  2015-09-01       Impact factor: 56.272

Review 2.  Mineralocorticoid Receptor Antagonists: a Comprehensive Review of Finerenone.

Authors:  Juan Simon Rico-Mesa; Averi White; Ashkan Ahmadian-Tehrani; Allen S Anderson
Journal:  Curr Cardiol Rep       Date:  2020-09-10       Impact factor: 2.931

3.  Design and Baseline Characteristics of the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease Trial.

Authors:  Luis M Ruilope; Rajiv Agarwal; Stefan D Anker; George L Bakris; Gerasimos Filippatos; Christina Nowack; Peter Kolkhof; Amer Joseph; Nicole Mentenich; Bertram Pitt
Journal:  Am J Nephrol       Date:  2019-10-30       Impact factor: 3.754

4.  KDIGO 2020 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease.

Authors: 
Journal:  Kidney Int       Date:  2020-10       Impact factor: 10.612

5.  Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes.

Authors:  George L Bakris; Rajiv Agarwal; Stefan D Anker; Bertram Pitt; Luis M Ruilope; Peter Rossing; Peter Kolkhof; Christina Nowack; Patrick Schloemer; Amer Joseph; Gerasimos Filippatos
Journal:  N Engl J Med       Date:  2020-10-23       Impact factor: 91.245

6.  Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial.

Authors:  Bertram Pitt; Lars Kober; Piotr Ponikowski; Mihai Gheorghiade; Gerasimos Filippatos; Henry Krum; Christina Nowack; Peter Kolkhof; So-Young Kim; Faiez Zannad
Journal:  Eur Heart J       Date:  2013-05-27       Impact factor: 29.983

7.  Finerenone and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Type 2 Diabetes.

Authors:  Gerasimos Filippatos; Stefan D Anker; Rajiv Agarwal; Bertram Pitt; Luis M Ruilope; Peter Rossing; Peter Kolkhof; Patrick Schloemer; Ingo Tornus; Amer Joseph; George L Bakris
Journal:  Circulation       Date:  2020-11-16       Impact factor: 29.690

8.  A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease.

Authors:  Gerasimos Filippatos; Stefan D Anker; Michael Böhm; Mihai Gheorghiade; Lars Køber; Henry Krum; Aldo P Maggioni; Piotr Ponikowski; Adriaan A Voors; Faiez Zannad; So-Young Kim; Christina Nowack; Giovanni Palombo; Peter Kolkhof; Nina Kimmeskamp-Kirschbaum; Alexander Pieper; Bertram Pitt
Journal:  Eur Heart J       Date:  2016-04-29       Impact factor: 35.855
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.